The table below shows Beam Therapeutics Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$345.10M
-$347.25M
-$149.19M
$22.53M
-$66.27M
-$95.74M
Capital expenditure
$14.95M
$8.95M
$33.73M
$48.95M
$46.81M
$16.36M
Investing cash flow
-$121.44M
$185.01M
$71.84M
-$461.34M
-$294.14M
-$100.12M
Dividends paid
-
-
-
-
-
BEAM operating cash flow (10-K history)
Beam Therapeutics Inc. reported operating cash flow of -$345.10M for fiscal year 2025. That is up 0.6% from -$347.25M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$72.00M (FY 2019) to -$345.10M. Figures come from the company's audited annual reports as filed with the SEC.
